The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Myriad Genetics, Inc’s current trading price is -81.95% away from its 52-week high, while its distance from the 52-week low is 38.78%. The stock’s price range for this period has been between $3.81 and $29.30 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 3.33 million for the day, a number notably higher than the average daily volume of 2.01 million over the last three months.
The market performance of Myriad Genetics, Inc’s stock has been turbulent in recent times.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Myriad Genetics, Inc (MYGN) has experienced a quarterly decline of -48.84% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 487.62M and boasts a workforce of 2700 employees.
Analyzing Trading Volume and Moving Average Trends
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for MYGN stands at 0.22. Similarly, the long-term debt-to-equity ratio is also 0.21.
MYGN Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. Year to date metric has recorded a loss of -61.42%.However, over the last six months, we can see a stronger performance of -67.49%. Over the last 30 days, the price of MYGN has leaped by -31.30%. And in the last five days, it has surged by 22.17%.
